Bio-Techne shares rose 20.9% in pre-market trading following an announcement that Merck KGaA has entered into a binding agreement to acquire the Minneapolis-based life sciences firm for $73 per share in cash. The stated purchase price implies a total enterprise value of roughly $11.3 billion.
The proposed cash offer represents a 36% premium to Bio-Techne's one-month volume-weighted average trading price. That premium immediately re-priced the stock toward the deal level and pushed its market value close to its 52-week high of $72.16.
Both companies' governance bodies approved the transaction - the agreement received unanimous approval from Bio-Techne's board of directors as well as the relevant corporate bodies of Merck KGaA. The companies said the deal is expected to close in late 2026 or early 2027, subject to customary regulatory clearances and a shareholder vote.
Merck KGaA indicated it will fund the acquisition with a mix of existing cash and newly raised debt, underlining the strategic intent behind the move to bolster its life sciences holdings. The statement highlighted Bio-Techne's product mix - including reagents, analytical instruments, and spatial biology platforms - as central assets that Merck KGaA aims to integrate into its portfolio.
The transaction and the resulting jump in Bio-Techne's share price came despite modest weakness in U.S. equity markets heading into the session. In the prior trading day, the S&P 500 had slipped 0.1% and the Nasdaq had declined 0.4%, with pressure concentrated in technology and energy sectors.
Within the life sciences tools sector, companies have been contending with softer demand stemming from weakened biotech and academic spending. That broader sector headwind makes the size of the acquisition premium notable, particularly after Bio-Techne had been trading nearer multi-year lows earlier in the year - including a 52-week low of $43.20.
Taken together, the companies said the definitive, board-approved, all-cash offer at a substantial premium is the dominant factor driving the pre-market move. The announcement has effectively compressed Bio-Techne's trading toward the $73 offer price, overshadowing macro and sector-level developments for the moment.
Contextual note: The companies have set expectations for customary regulatory review and a shareholder vote before the transaction can close in the projected late 2026 to early 2027 timeframe.